NO20021932D0 - Medikament egnet til behandling av ondartede tumorer - Google Patents
Medikament egnet til behandling av ondartede tumorerInfo
- Publication number
- NO20021932D0 NO20021932D0 NO20021932A NO20021932A NO20021932D0 NO 20021932 D0 NO20021932 D0 NO 20021932D0 NO 20021932 A NO20021932 A NO 20021932A NO 20021932 A NO20021932 A NO 20021932A NO 20021932 D0 NO20021932 D0 NO 20021932D0
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- malignant tumors
- medication suitable
- compounds
- medication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16140799P | 1999-10-25 | 1999-10-25 | |
SE9903838A SE9903838D0 (sv) | 1999-10-25 | 1999-10-25 | Novel compounds |
US21281600P | 2000-06-21 | 2000-06-21 | |
SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20021932D0 true NO20021932D0 (no) | 2002-04-24 |
NO20021932L NO20021932L (no) | 2002-06-21 |
NO323320B1 NO323320B1 (no) | 2007-03-12 |
Family
ID=27484521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021932A NO323320B1 (no) | 1999-10-25 | 2002-04-24 | Medikament egnet til behandling av ondartede tumorer |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1224172B1 (no) |
JP (1) | JP3950337B2 (no) |
KR (2) | KR100674160B1 (no) |
AT (1) | ATE358668T1 (no) |
AU (1) | AU775057B2 (no) |
CA (1) | CA2386775C (no) |
CZ (1) | CZ298534B6 (no) |
DE (1) | DE60034240T2 (no) |
DK (1) | DK1224172T3 (no) |
EE (1) | EE200200207A (no) |
ES (1) | ES2280258T3 (no) |
HK (1) | HK1049830A1 (no) |
HR (1) | HRP20020353A2 (no) |
HU (1) | HU229072B1 (no) |
IL (2) | IL148782A0 (no) |
IS (1) | IS2750B (no) |
NO (1) | NO323320B1 (no) |
NZ (1) | NZ518296A (no) |
SE (1) | SE0002320D0 (no) |
UA (1) | UA73748C2 (no) |
WO (1) | WO2001030758A1 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
CA2810655C (en) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
BRPI0617477A2 (pt) | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2035001B1 (en) | 2006-06-12 | 2011-11-09 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
PL2682120T3 (pl) | 2007-12-20 | 2017-02-28 | Teva Pharmaceutical Industries, Ltd. | Stabilne preparaty lakwinimodu |
BRPI0913518A2 (pt) | 2008-09-03 | 2016-07-26 | Teva Pharma | composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
AU2011314411B2 (en) * | 2010-10-14 | 2014-06-12 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AhR activators. |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
CN104470518A (zh) | 2012-02-27 | 2015-03-25 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
BR112015010193A2 (pt) * | 2012-11-07 | 2017-07-11 | Teva Pharma | sais de amina de laquinimod |
KR20150143499A (ko) | 2013-03-14 | 2015-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법 |
AU2015316824B2 (en) | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
KR102525805B1 (ko) * | 2014-11-19 | 2023-04-25 | 액티브 바이오테크 에이비 | 백혈병 치료용 퀴놀린 카르복사미드 |
WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
EP4114368A1 (en) | 2020-03-03 | 2023-01-11 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
US20240091215A1 (en) | 2021-01-18 | 2024-03-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
IL308542A (en) | 2021-05-25 | 2024-01-01 | Active Biotech Ab | Multiparticles of tesquinimod and their use |
WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
WO2023039275A1 (en) * | 2021-09-13 | 2023-03-16 | Eli Lilly And Company | Ahr agonists |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 EP EP00973329A patent/EP1224172B1/en not_active Expired - Lifetime
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en active IP Right Grant
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active IP Right Cessation
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active IP Right Cessation
-
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-23 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation
-
2003
- 2003-01-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20021932L (no) | Medikament egnet til behandling av ondartede tumorer | |
YU23202A (sh) | Lekovi za tretman malignih tumora | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
BR0112589A (pt) | Derivados de heteroarila e sua aplicação como medicamento | |
SE9904505D0 (sv) | Novel compounds | |
BRPI0519567A2 (pt) | heterociclos tricÍclicos, sua fabricaÇço e uso como agentes farmacÊuticos | |
RU2011138835A (ru) | Применение производного рапамицина | |
SE0104140D0 (sv) | Novel Compounds | |
PL367682A1 (en) | Dolastatin 10 derivatives | |
BR0309355A (pt) | 2-(2,6-diclorofenil)-diarilimidazóis | |
SE9901875D0 (sv) | Novel compounds | |
GB0112348D0 (en) | Compounds | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
JO2390B1 (en) | Diphenylcarboxamides act as lipid-lowering agents | |
BR0112807A (pt) | Derivados de indol e sua aplicação como medicamento | |
ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
NO20030420L (no) | Medikament for immunoterapi av maligne tumorer | |
CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας | |
SE0004827D0 (sv) | Therapeutic compounds | |
TW200505913A (en) | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents | |
WO2002098399A3 (en) | Cancer treatment method and compositions comprising compounds of the ginger family |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |